Merck (MRK) announced on Monday that the Canadian regulator, Health Canada, has granted approval for its cancer drug Keytruda ...

Summit Therapeutics' leading candidate is showing promise in a key oncology market. Three years ago, Summit Therapeutics ...

Merck is seeking ways to prepare for a significant upcoming patent cliff. The company has just announced another acquisition ...

Thanks to a well-timed capital raising ahead of a major setback, Percheron lives on. Can it capitalise on a promising new asset?

Michelle Xia gained experience at U.S. pharmaceutical firms before launching her own biotech company back home in China. In a ...

Overview of Breast Cancer Therapeutics MarketThe Global Breast Cancer Therapeutics Market is valued at USD 33.83 Billion in ...

Viking Therapeutics is targeting two monster markets. David Jagielski (CRISPR Therapeutics): Biotech company CRISPR ...

Merck aims to boost its business by buying Verona Pharma for $10 billion. Through the deal, it will add Ohtuvayre -- a ...

"These breakthroughs have been lifesaving — for me and so many others who rely on cancer therapy." writes one reader.

Merck & Company, Inc. (NYSE:MRK) is one of the high-margin pharma stocks to buy now. Jefferies has raised its price target on ...

President Trump is readying plans for industry-specific tariffs to kick in alongside his country-by-country duties in two ...

In this week’s edition of InnovationRx, we look at how Daniel Nadler became a billionaire building a ChatGPT for doctors, big ...